How Global Regulatory Trends Are Quietly Shaping FDA Reviews

Why Global Regulatory Decisions Now Influence FDA Reviews

Introduction

A Silicon Valley startup believed it had prepared a flawless submission.

Its artificial intelligence diagnostic device was supported by strong clinical data, the regulatory pathway seemed clear, and the team submitted what it believed was a well-structured 510(k) application to the U.S. Food and Drug Administration.

Then the review stalled.

Unknown to the startup, a nearly identical device had recently been denied approval in Europe by the European Medicines Agency due to concerns about algorithmic risk and clinical validation.

That decision influenced the FDA’s line of questioning.

What followed was an eight-month regulatory delay, a lost competitive lead, and a costly scramble to address concerns that could have been anticipated.

Scenarios like this are becoming more common.

In 2025, the International Medical Device Regulators Forum released two major guidance documents addressing software and artificial intelligence in medical devices.

These documents represent more than routine regulatory updates.

They reflect a coordinated global shift toward shared expectations for transparency, bias mitigation, lifecycle monitoring, and AI risk management.

For U.S. startups, the implication is clear:

Regulatory strategies that ignore global precedent are no longer merely incomplete.

They are risky.

IMDRF Is Driving Global Alignment for AI Devices

The new IMDRF guidance documents signal a turning point in how regulators assess AI-enabled medical devices.

The principles of Good Machine Learning Practice (GMLP) outlined in the IMDRF framework align closely with guidance jointly developed by:

• the U.S. Food and Drug Administration
• Health Canada
• the Medicines and Healthcare products Regulatory Agency

This alignment introduces a shared regulatory philosophy built around three central principles.

AI models must be transparent and explainable. Regulators increasingly expect manufacturers to demonstrate how algorithms reach clinical conclusions.

Robust data governance is essential. Training datasets must be representative, unbiased, and traceable.

Risk management must span the entire product lifecycle. AI systems must be monitored continuously after deployment.

These principles are rapidly evolving from guidance into baseline regulatory expectations.

The second IMDRF document expands the scope of software regulation by introducing broader definitions for medical device software.

It clarifies terminology surrounding:

• Software as a Medical Device (SaMD)
• Software in a Medical Device (SiMD)
• Medical Device Software (MDSW)

This alignment helps harmonize terminology across global frameworks such as the EU Medical Device Regulation and In Vitro Diagnostic Regulation.

Global Regulatory Precedent Is Shaping FDA Reviews

The FDA no longer operates in isolation.

Regulatory collaboration between major health authorities has significantly increased over the past decade.

As of March 2025, the FDA had authorized more than 1,000 AI and machine learning-enabled medical devices, demonstrating the agency’s growing engagement with AI-driven healthcare technologies.

However, regulatory collaboration means that global decisions increasingly influence U.S. review processes.

Joint work between the FDA, Health Canada, and the MHRA has established ten core principles guiding the development and evaluation of machine learning medical devices.

These shared frameworks encourage regulators to evaluate devices using similar safety and performance standards.

Evidence from regulatory approvals suggests that major agencies often reach similar conclusions when evaluating comparable products.

This means decisions in Europe or Canada may indirectly shape how similar products are assessed in the United States.

For startups, ignoring international regulatory precedent is no longer viable.

Regulatory Intelligence Across Markets Is Now Essential

Modern regulatory strategy requires awareness across multiple jurisdictions.

Companies must now monitor how regulators interpret and implement emerging frameworks.

The GMLP framework highlights five operational pillars for AI-enabled medical devices.

Multidisciplinary collaboration Regulatory, clinical, engineering, and data science teams must work together from early development stages.

Data representativeness Training data must account for population variability and real-world clinical use.

Model explainability Algorithms must provide transparent reasoning and confidence indicators.

Continuous performance monitoring Manufacturers must detect algorithm drift and implement update protocols.

Ethical system design Users must retain oversight over AI-driven clinical decisions.

These pillars increasingly serve as universal expectations rather than optional best practices.

Companies that track how regulators apply these principles gain significant strategic advantages.

International Standards Are Creating a Global Compliance Framework

Shared international standards are becoming the backbone of AI medical device regulation.

Several key frameworks now influence regulatory expectations across markets.

These include:

• ISO/IEC 23053 – AI and machine learning lifecycle framework
• ISO/IEC 42001 – AI management system standard
• ISO/IEC 23894 – AI risk management framework
• AAMI CR34971 – risk management guidance for software medical devices
• NIST AI Risk Management Framework – U.S. AI governance framework

Startups that align with these standards early often experience smoother regulatory reviews across multiple jurisdictions.

Market Access Patterns Are Changing

Regulatory approval strategies have evolved significantly over the past two decades.

Between 2005 and 2010, most medical devices received approval in Europe before entering the U.S. market.

Today, the trend is increasingly reversed.

The complexity of EU MDR requirements and limited Notified Body capacity has pushed many manufacturers to pursue FDA approval first.

However, this strategy introduces trade-offs.

Devices launched first in Europe historically showed higher post-market safety alert rates than those initially approved in the United States.

Meanwhile, the EU MDR’s extensive clinical evidence requirements—such as Clinical Evaluation Reports and Post-Market Clinical Follow-Up—can dramatically increase development timelines.

Understanding these market dynamics allows startups to make informed regulatory sequencing decisions.

Global Trends Reach the U.S. Faster Than Before

Regulatory trends now move across borders more quickly than ever.

Developments within international regulatory frameworks often influence U.S. expectations within a short timeframe.

Cybersecurity provides a clear example.

The IMDRF cybersecurity framework introduces a Total Product Lifecycle approach covering:

• development
• deployment
• end-of-support timelines

It also emphasizes transparency through tools such as the Software Bill of Materials (SBOM).

These concepts, first emphasized in international frameworks, are now shaping expectations within FDA regulatory reviews.

Startups that anticipate global regulatory trends can position their submissions ahead of emerging requirements.

Implementing Global Regulatory Intelligence

To operate effectively in this environment, startups must embed global regulatory awareness into their internal processes.

Practical steps include:

Building cross-functional regulatory teams Involve regulatory, clinical, engineering, and data science expertise early in development.

Conducting global risk assessments Evaluate AI system risks against international regulatory expectations.

Developing comprehensive technical documentation Include algorithm training data, validation protocols, and explainability models.

Implementing lifecycle change management Define update triggers, retraining protocols, and performance monitoring processes.

Monitoring global regulatory guidance continuously Track evolving frameworks from IMDRF and major health authorities.

Companies that incorporate global precedent early often produce stronger submissions and avoid costly regulatory delays.

Regulatory Intelligence Is a Business Advantage

Regulatory strategy directly affects commercial success.

Developing high-risk medical devices often requires investments of tens of millions of dollars.

Unexpected regulatory obstacles can significantly delay market entry and increase development costs.

Global regulatory intelligence reduces uncertainty by identifying potential challenges early in the development lifecycle.

It also enables startups to prioritize markets strategically.

For example, reimbursement rates in the United States can be substantially higher than in European markets for certain device categories.

Understanding these economic differences helps companies design smarter market entry strategies.

Regulatory intelligence is therefore not just a compliance tool.

It is a strategic business asset.

Building a Regulatory Intelligence System

The regulatory landscape for AI-enabled medical devices will continue evolving rapidly.

The IMDRF guidance documents released in 2025 represent only the beginning of deeper global regulatory coordination.

Successful startups will be those that transform regulatory information into structured, actionable intelligence.

This means building systems capable of:

• tracking global regulatory precedent
• monitoring emerging guidance
• identifying strategic opportunities for market entry

Companies that develop strong regulatory intelligence capabilities will navigate approval pathways faster and with greater confidence.

At SMEDTEC, we help MedTech companies build regulatory intelligence systems that convert complex global regulatory information into practical strategic insights.

Contact SMEDTEC today to learn how structured regulatory intelligence can accelerate your path to market.